SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction | MicrobiomeTrials← Back to trialsNCT07597902
SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-06-01Est. Completion: 2028-06-30
Enrollment target: 150 participants Locations- The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE), New York, New York, United States
Other microbiome trials you might be interested in
Post-Acute COVID-19 SyndromeFatigue
The primary objective of this study is to conduct a 16-week randomized controlled trial aimed at investigating the effec…
Baltimore, United StatesEst. completion Jun 30, 2028
Post-Acute COVID-19 Syndrome
Background:
SARS-CoV-2 is the virus that causes COVID-19. Some people who recover from an acute COVID-19 infection may …
Bethesda, United StatesEst. completion Jan 1, 2028
Completed
COVID-19 is a systemic inflammatory disease involving many organs including the lungs, vascular system liver and myocard…
Baltimore, United StatesCompleted May 15, 2026